期刊文献+

超声造影预测乳腺癌新辅助化疗疗效分析 被引量:12

Prediction efficacy of neoadjuvant chemotherapy in the treatment of breast cancer with contrast-enhanced ultrasound
下载PDF
导出
摘要 目的探讨超声造影参数预测乳腺癌新辅助化疗疗效的应用价值。方法 56例乳腺癌患者分别于新辅助化疗前及第2次化疗结束后进行超声造影检查。记录超声造影参数及4-6个周期新辅助化疗后的病理学疗效,比较新辅助化疗前、后超声造影参数的差异及不同病理学疗效分组间超声造影参数的差异。结果 56例乳腺癌病灶经新辅助化疗2个周期后的超声造影峰值强度(17.82±3.29 db)低于化疗前(23.80±3.74 db),差异有统计学意义(t=19.948,P〈0.001)。化疗前、后两次乳腺癌病灶超声造影峰值强度变化率与病理反应分级呈正相关(spearman r=0.839,P〈0.001)。4-6个周期新辅助化疗后的病理有效组与无效组的峰值强度变化率分别为0.28±0.07和0.16±0.04(t=5.27,P=0.026)。结论超声造影参数中峰值强度变化率有助于预测乳腺癌新辅助化疗的疗效。 Objective To predict the efficacy of neo- adjuvant chemotherapy( NAC) in the treatment of breast cancer with the parameters of contrast- enhanced Ultrasound( CEUS). Methods Fifty- six patients with breast cancer accepted CEUS examination respectively before and after two cycles NAC. Parameters of CEUS and Tumor Response Grade( TRG) after mastectomy of all cases after 4 - 6 cycles NAC were recorded. Parameters of CEUS before and after NAC were compared,and the parameters between different pathologic effect groups were analyzed. Results Peak intensity of 56 cases of breast cancer lesions before and after two cycles NAC during CEUS were( 23. 80 ± 3. 74) db and( 17. 82 ±3. 29) db,respectively. The difference was statistically significant( t = 19. 948,P〈0. 001). Change rate of peak intensity( CROPI) after two cycles NAC of all lesions were positively correlated with TRG( spearmanr = 0. 839,P〈0. 001). The differences of CROPI between effectivegroup( 0. 28 ± 0. 07) and ineffective group( 0. 16 ± 0. 04) after mastectomy were significant( t = 5. 27,P = 0. 026). Conclusion Change rate of peak intensity of CEUS can predict the effect of neo- adjuvant chemotherapy for breast cancer.
出处 《临床和实验医学杂志》 2014年第21期1770-1773,共4页 Journal of Clinical and Experimental Medicine
基金 首都医科大学基础临床结合课题(NO:12JL39) 首都卫生发展科研专项(NO:首发2011-1002-02)
关键词 乳腺肿瘤 新辅助化疗 超声检查 疗效 预测 Breast neoplasms Neo-adjuvant chemotherapy Ultrasonography Effect Prediction
  • 相关文献

参考文献13

  • 1Trudeau M, Sinclair SE, Clemons M. Neoadjuvant taxanes in the treat- ment of non- metastatic breast cancer: a systematic review[ J:. Cancer Treat Rev, 2005,31 (4) :283 -302.
  • 2中国抗癌协会乳腺癌专业委员会.中国抗癌协会乳腺癌诊治指南与规范(2011版)[J].中国癌症杂志,2011,21(5):367-417. 被引量:268
  • 3Ogston K, Miller I, Payne S, et al. A new histological grading system to assess response of breast cancers to primary chemotherapy: prognostic significance and survival[ J]. Breast, 2003,12 (5) :320 - 327.
  • 4Yeh E, Slanetz P, Kopans DB, et al. Prospective comparison of mam- mography, sonography, and MRI in patients undergoing neoadjuvant chemotherapy for palpable breast cancer[ J]. Am J Roentgenol, 2005, 184(3) :868 -877.
  • 5Shin HJ, Kim HH, Ahn JH, et al. Comparison of mammography, sonography, MRI and clinical examination in patients with locally ad- vanced or inflammatory breast cancer who underwent neoadjuvant chem- otherapy[ J]. Br J Radiol, 2011,84( 1003 ) :612 - 620.
  • 6Partridge SC, Gibbs JE, Lu Y, et al. Accuracy of MR imaging for re- vealing residual breast cancer in patients who have undergone neoadju- rant chemotherapy[ J]. AJR, 2002,179 ( 5 ) : 1193 - 1199.
  • 7赵兴娟,高润芳,杨璇,张志玲,郝艳霞.局部晚期乳腺癌新辅助化疗FEC与TEC方案近期疗效观察[J].临床和实验医学杂志,2013,12(13):1068-1069. 被引量:17
  • 8Ore1 S. Who should have breast magnetic resonance imaging evaluation [ J] ? J Clin Oncol, 2008,26 (5) :703 - 711.
  • 9Chagpar AB, Middleton LP, Sahin AA, et al. Accuracy of Physical ex- amination, Ultrasonography, and Mammography in predicting residual pathologic tumor size in patients treated with neoadjuvant chemotherapy [J]. Ann Surg, 2006,243(2) :257 -264.
  • 10Broillet A, Hantson J, Ruegg C, et al. Assessment of microvascular perfusion changes in a rat breast tumor model using SonoVue to monitor the effects of different anti - angiogenic therapies [ J ]. Acad Radiol, 2005,12 ( Suppl 1 ) : $28 - 33.

二级参考文献5

共引文献283

同被引文献138

引证文献12

二级引证文献84

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部